26 - 30 May 2018
Munich, Germany

Industry Programme

Company Sponsored Symposia


Sunday, 27 May 2018

 

Company Sponsored Symposium (CSS 1)
ALK
10:30 – 12:00, Hall 14b
ALK Logo

Shaking the trees: introducing the tree SLIT-tablet for birch group allergy

Chairs: Lone Winther, Denmark
Natalija Novak, Germany

Birch group pollen allergy in Europe: understanding the burden
Erkka Valovirta, Finland

Finding the right dose: results from an environmental exposure chamber
Anne Marie Salapatek, Canada

Confirming efficacy beyond birch: results from the European phase III field trial
Tilo Biedermann, Germany


Company Sponsored Symposium (CSS 2) Novartis Pharma AG 
13:30 – 15:00, Hall 5
novartis logo pos rgb

Why asthma is still uncontrolled in the 21st century: insight, impact and improvement      Livestreaming Session

Chair: Marc Humbert, France

Welcome and introduction
Marc Humbert, France

Characteristics and challenges of uncontrolled asthma
Marc Humbert, France

Inflammatory mechanisms in asthma: targets to gain control
Oscar Palomares, Spain

The challenges of managing asthma patients who smoke
Ashley Woodcock, United Kingdom

Uncontrolled asthma and comorbid nasal polyps: exploring the link
Claus Bachert, Belgium

Uncontrolled paediatric asthma: additional treatment challenges?
Adnan Custovic, United Kingdom

Chair-facilitated panel discussion and audience Q&A
All faculty



Company Sponsored Symposium (CSS 3) 
AstraZeneca PLC
15:30 – 17:00, Hall 14a
astrazeneca

Optimising Management of Severe Eosinophilic Asthma: An Interactive Expert Discussion

Chair: Christian Taube, Germany

Pathophysiology and Diagnostic Considerations
Christian Taube, Germany

Emerging Data and New Therapeutic Options
Sameer Mathur, United States

Insights From Patient Cases
David Jackson, United Kingdom


Monday, 28 May 2018

 

Company Sponsored Symposium (CSS 4)
Mylan 
10:45 – 12:15, Hall 14a
Mylan


5 minutes to change AR patients’ lives


Chair: Ludger Klimek, Germany

Introduction
Ludger Klimek, Germany

The need for speed
Peter Hellings, Belgium

Breaking the 5 minute speed barrier
David Price, United Kingdom

ARIA phase 4: Fast track to change
Jean Bousquet, France

Conclusion and Closing
Ludger Klimek, Germany


 

Company Sponsored Symposium (CSS 5)
HAL Allergy 
13:45 – 15:15, Hall 5
hal allergy

Allergy in a changing world       Livestreaming Session

Chairs: Ronald van Ree, The Netherlands
Dirk-Jan Opstelten, The Netherlands

Climate Change – its effect on the allergy epidemic
Jeroen Buters, Germany

Biologics versus AIT – who will win?
Nikos Papadopoulos, United Kingdom/Greece

AIT: fixing current and future needs
Moisés Antonio Calderón, United Kingdom


Company Sponsored Symposium (CSS 6) Allergopharma GmbH & Co. KG 
15:45 – 17:15, Hall 5
Allergopharma Logo 2018

Allergoids – ready for the future

Chairs: Carsten Schmidt-Weber, Germany
Petra Zieglmayer, Austria

Detouring AIT development: lessons learned
Jörg Kleine-Tebbe, Germany

House dust mite SCIT: focus on asthmatic patients
Marek Jutel, Poland

Short cuts in pollen SCIT: a step towards better patient care
Matthias Kopp, Germany


Tuesday, 29 May 2018


Company Sponsored Symposium (CSS 7)
Thermo Fisher Scientific
10:30 - 12:00, Hall 14b
logo thermofisher


Allergic Asthma – Prediction, Prognosis and Management

Chair: Adnan Custovic, United Kingdom

Welcome to symposium - Should allergic sensitisation be included in diagnostic algorithms for asthma?
Adnan Custovic, United Kingdom

The importance of IgE in asthma

Robert Lemanske, United States

Early prediction and prevention of allergy and asthma

Karin Lødrup Carlsen, Norway

Diagnosis of respiratory allergy and use of CRD in ASIT

Pascal Demoly, France

Closing remarks and future directions

Adnan Custovic, United Kingdom


 

Company Sponsored Symposium (CSS 8) STALLERGENES GREER 
13:30 – 15:00, Hall 14a
regulatory with tagline cmyk

Are you concerned with your allergic patients' disease evolution?  Take a BREATH of Real World Evidence       Livestreaming Session

Is it time to think bigger: how can Real World Evidence change the game?
Adam Fox, United Kingdom

What is the impact of AIT on the disease evolution of respiratory allergy patients?
 ·         New results from a French study with AIT-tablets for grass pollen allergies.
           Pascal Demoly, France

·         New results from a German study with AIT for birch pollen allergies.  
           Stefan Zielen, Germany / Ulrich Wahn , Germany

Round-table discussion

Finding answers: how will new Real World Evidence influence clinical decision making?
Pascal Demoly, France; Adam Fox, United Kingdom; Ulrich Wahn, Germany; Stefan Zielen, Germany